Changes in US stocks | Hims & Hers Health (HIMS.US) to launch exclusive oral testosterone therapy, rises more than 7%

Zhitongcaijing · 09/10/2025 15:25

The Zhitong Finance App learned that Hims & Hers Health (HIMS.US) shares rose higher on Wednesday. As of press release, the stock had risen more than 7% to $51.39. According to the news, the company announced that it will exclusively launch an oral testosterone drug KYZATREX® on its platform in 2026 through a partnership with Marius Pharmaceuticals, a leader in testosterone therapy innovation. This drug has been approved by the US Food and Drug Administration, does not require injections, and is more convenient to use. According to clinical data, KYZATREX® can restore normal testosterone levels in up to 96% of men while doubling “free testosterone.” Free testosterone is thought to be closely related to energy, drive, and physical performance, and the drug enhances efficacy while maintaining a low rate of adverse reactions.